Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jae-Joon Yim

Showing results (271-280 of 288) with videos related to

Pageof 29
Sort By:
American Journal of Respiratory and Critical Care Medicine|September 15, 2018
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by David E Griffith, Gina Eagle, Rachel Thomson, et al.
Annals of the American Thoracic Society|February 13, 2016
Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment OutcomesYoung Ae Kang, Tae Sun Shim, Won-Jung Koh, et al.
Lancet (London, England)|December 15, 2022
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South KoreaJeongha Mok, Myungsun Lee, Deog Kyeom Kim, et al.
Trials|February 15, 2017
Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trialJi Yeon Lee, Deog Kyeom Kim, Jung-Kyu Lee, et al.
American Journal of Respiratory and Critical Care Medicine|August 10, 2013
Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosisWon-Jung Koh, Seung Heon Lee, Young Ae Kang, et al.
Chest|April 11, 2020
The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic: A Multinational Consensus Statement From the Fleischner SocietyGeoffrey D Rubin, Christopher J Ryerson, Linda B Haramati, et al.
Trials|January 18, 2019
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trialMyungsun Lee, Jeongha Mok, Deog Kyeom Kim, et al.
Radiology|April 8, 2020
The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner SocietyGeoffrey D Rubin, Christopher J Ryerson, Linda B Haramati, et al.
American Journal of Respiratory Cell and Molecular Biology|February 8, 2017
Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 SubjectsRobert Busch, Brian D Hobbs, Jin Zhou, et al.
The Lancet. Infectious Diseases|November 28, 2018
Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trialJung-Kyu Lee, Ji Yeon Lee, Deog Kyeom Kim, et al.
Pageof 29

Showing results (271-280 of 288) with videos related to

Sort By:
Pageof 29
American Journal of Respiratory and Critical Care Medicine|September 15, 2018
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by David E Griffith, Gina Eagle, Rachel Thomson, et al.
Annals of the American Thoracic Society|February 13, 2016
Choice between Levofloxacin and Moxifloxacin and Multidrug-Resistant Tuberculosis Treatment OutcomesYoung Ae Kang, Tae Sun Shim, Won-Jung Koh, et al.
Lancet (London, England)|December 15, 2022
9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South KoreaJeongha Mok, Myungsun Lee, Deog Kyeom Kim, et al.
Trials|February 15, 2017
Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: study protocol for a prospective, multicenter, randomized, open-label, phase II trialJi Yeon Lee, Deog Kyeom Kim, Jung-Kyu Lee, et al.
American Journal of Respiratory and Critical Care Medicine|August 10, 2013
Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosisWon-Jung Koh, Seung Heon Lee, Young Ae Kang, et al.
Chest|April 11, 2020
The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic: A Multinational Consensus Statement From the Fleischner SocietyGeoffrey D Rubin, Christopher J Ryerson, Linda B Haramati, et al.
Trials|January 18, 2019
Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trialMyungsun Lee, Jeongha Mok, Deog Kyeom Kim, et al.
Radiology|April 8, 2020
The Role of Chest Imaging in Patient Management during the COVID-19 Pandemic: A Multinational Consensus Statement from the Fleischner SocietyGeoffrey D Rubin, Christopher J Ryerson, Linda B Haramati, et al.
American Journal of Respiratory Cell and Molecular Biology|February 8, 2017
Genetic Association and Risk Scores in a Chronic Obstructive Pulmonary Disease Meta-analysis of 16,707 SubjectsRobert Busch, Brian D Hobbs, Jin Zhou, et al.
The Lancet. Infectious Diseases|November 28, 2018
Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trialJung-Kyu Lee, Ji Yeon Lee, Deog Kyeom Kim, et al.
Pageof 29